Regeneron has been a leader in the discovery and characterization of a new class of proteins, called neurotrophins, which promote the growth of nerve cells. Members of this family of proteins include nerve growth factor (NGF), BDNF (brain-derived neurotrophic factor), NT-3, and NT-4/5. Our most advanced product candidate is fasinumab (REGN475), a fully-human antibody that specifically targets NGF.

Steven Weinstein Steven Weinstein, M.D., Ph.D. VP Clinical Sciences Immunology and Inflammation

Clinical Trials

Regeneron has investigational product candidates progressing through all stages of human clinical trials.

See if there are clinical trials that might be right for you

This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.

Form content here please :)